目的为建立能稳定表达人葡糖醛酸转移酶UDPGT1A9蛋白的CHL UDPGT1A9转基因细胞系，并鉴定其对药物的葡糖醛酸缀合活性。
AIM To establish a cell line CHL UDP glucuronosyltransferase gene (UDPGT1A9) which will stably express human UDPGT1A9 protein and determine the activity of expressed UDPGT1A9 in drug glucuronidation.
所述药物组合物包含磷脂酶(PL)多肽和蛋白转导结构域(PTD)的缀合物。
The pharmaceutical compositions contain a conjugate of a phospholipase (PL) polypeptide and a protein transduction domain (PTD).
所述抗癌抗体可以与毒素、酶、放射性化合物以及造血细胞缀合。
The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.
本发明涉及使用单个的肽缀合纳米新月体表面增强拉曼散射（SERS）探 针以至少纳摩的灵敏度进行蛋白酶的体外检测。
This invention pertains to the in vitro detection of proteases using a single peptide-conjugate nanocrescent surface enhanced Raman scattering (SERS) probes with at least nanomolar sensitivity.
本发明涉及使用单个的肽缀合纳米新月体表面增强拉曼散射（SERS）探 针以至少纳摩的灵敏度进行蛋白酶的体外检测。
This invention pertains to the in vitro detection of proteases using a single peptide-conjugate nanocrescent surface enhanced Raman scattering (SERS) probes with at least nanomolar sensitivity.
应用推荐